Cargando…
Malaria Vaccines: From the Past towards the mRNA Vaccine Era
Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536368/ https://www.ncbi.nlm.nih.gov/pubmed/37766129 http://dx.doi.org/10.3390/vaccines11091452 |
_version_ | 1785112849237934080 |
---|---|
author | Tsoumani, Maria E. Voyiatzaki, Chrysa Efstathiou, Antonia |
author_facet | Tsoumani, Maria E. Voyiatzaki, Chrysa Efstathiou, Antonia |
author_sort | Tsoumani, Maria E. |
collection | PubMed |
description | Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines’ evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates. |
format | Online Article Text |
id | pubmed-10536368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105363682023-09-29 Malaria Vaccines: From the Past towards the mRNA Vaccine Era Tsoumani, Maria E. Voyiatzaki, Chrysa Efstathiou, Antonia Vaccines (Basel) Review Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines’ evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates. MDPI 2023-09-04 /pmc/articles/PMC10536368/ /pubmed/37766129 http://dx.doi.org/10.3390/vaccines11091452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tsoumani, Maria E. Voyiatzaki, Chrysa Efstathiou, Antonia Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title | Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title_full | Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title_fullStr | Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title_full_unstemmed | Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title_short | Malaria Vaccines: From the Past towards the mRNA Vaccine Era |
title_sort | malaria vaccines: from the past towards the mrna vaccine era |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536368/ https://www.ncbi.nlm.nih.gov/pubmed/37766129 http://dx.doi.org/10.3390/vaccines11091452 |
work_keys_str_mv | AT tsoumanimariae malariavaccinesfromthepasttowardsthemrnavaccineera AT voyiatzakichrysa malariavaccinesfromthepasttowardsthemrnavaccineera AT efstathiouantonia malariavaccinesfromthepasttowardsthemrnavaccineera |